Sense Neuro Diagnostics

Sense Neuro Diagnostics is a US-based company specializing in non-invasive neurodiagnostic technologies, focusing on rapid detection of stroke subtypes and traumatic brain injuries using innovative technology. Founded in 2017 and headquartered in Cincinnati, US, Sense Neuro Diagnostics develops advanced technologies for neurodiagnosis. In September 2025, Sense Diagnostics, Inc. raised USD 17 million in series B funding from unspecified investors.

Sense Neuro Diagnostics specializes in developing non-invasive neurodiagnostic technologies, primarily focusing on rapid detection of stroke subtypes and traumatic brain injury (TBI). The company's flagship product, NeuroHawk, employs advanced radio frequency (RF) technology to scan the entire cranial vault in just 2. 5 seconds, analyzing 360 data points per scan. This technology is designed for real-time assessment and continuous monitoring of neurological status, offering critical insights for medical personnel in emergency settings such as field triage, emergency departments, and continuous hospital monitoring.

By targeting healthcare professionals, including emergency medical technicians and hospital clinicians, Sense Neuro aims to enhance patient care by facilitating timely treatments that can prevent long-term disability and death. The company is pursuing entry into various geographical markets, with a strategic focus on the United States and Europe, where the demand for innovative neurodiagnostic solutions is significant. Sense Neuro Diagnostics operates on a B2B transaction model, primarily collaborating with healthcare institutions, including hospitals and emergency medical services, to deliver its neurodiagnostic solutions. The revenue streams are generated through direct sales of their products, including NeuroHawk, as well as potential partnerships with medical facilities that integrate their technology into existing protocols for stroke and TBI management.

The structure of transactions includes one-time purchases and possible service agreements for ongoing support and updates. As the company advances towards FDA clearance and commercial launch, the pricing strategy will reflect the value proposition of rapid, non-invasive neurological assessments that significantly improve patient outcomes in critical care environments. In September 2025, Sense Diagnostics, Inc. raised USD 17 million in venture funding, which will be utilized to support the development of new products and the expansion into new markets.

The company plans to enhance its product lineup and focus on increasing its presence in the U. S. and Europe by the end of 2026, capitalizing on the growing demand for innovative neurodiagnostic solutions.